Business · 19/01/2006Updated: 10/17/2026 · 1 min read
FDA Withdraws Approval of 43 Abbreviated New Drug Applications by Able Laboratories, Inc.
Summary
The Food and Drug Administration (FDA) is withdrawing approval of 43 abbreviated new drug applications (ANDAs) submitted by Able Laboratories, Inc. (Able Labs), due to the discontinuation of the corresponding drug products. Able Labs has requested the withdrawal of approval for these applications.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →